US Patent

US12257236 — Oral formulations of metronidazole and methods of treating an infection using same

Method of Use · Assigned to Appili Therapeutics Inc · Expires 2039-01-16 · 13y remaining

Vulnerability score 75/100 Vulnerable — likely target for IPR or design-around

What this patent protects

This patent protects oral formulations of metronidazole and methods of treating an infection using these formulations.

USPTO Abstract

The present disclosure provides oral pharmaceutical compositions comprising: 1) metronidazole or a pharmaceutically acceptable salt thereof; and magnesium aluminum silicate; or 2) metronidazole or a pharmaceutically acceptable salt thereof; magnesium aluminum silicate; and a flavoring agent. Methods of treating infection utilizing the oral pharmaceutical compositions are also provided.

Drugs covered by this patent

Metro I.V. In Plastic Container (METRONIDAZOLE) · Baxter

FDA Patent Use Codes

When a patent is method-of-use, FDA lists it once per applicable indication ("U-code"). Each U-code carves out a specific therapeutic use that generic filers must either license or design around.

Code	Description	Drug
`U-3169`	—	Metro I.V. In Plastic Container

Patent Metadata

Patent number: US12257236
Jurisdiction: US
Classification: Method of Use
Expires: 2039-01-16
Drug substance claim: No
Drug product claim: Yes
Assignee: Appili Therapeutics Inc
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.